
Dr Agarwal's Health (AGARWALEYE) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
4.9B
Gross Profit
2.1B
43.48%
Operating Income
649.1M
13.32%
Net Income
380.6M
7.81%
EPS (Diluted)
₹0.95
Balance Sheet Metrics
Total Assets
36.7B
Total Liabilities
17.4B
Shareholders Equity
19.3B
Debt to Equity
0.91
Cash Flow Metrics
Revenue & Profitability Trend
Dr Agarwal's Health Income Statement From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Revenue | 10.4B | 8.4B | 10.2B | 7.0B |
Cost of Goods Sold | 6.1B | 4.7B | 5.6B | 3.9B |
Gross Profit | 4.3B | 3.6B | 4.6B | 3.1B |
Gross Margin % | 41.4% | 43.3% | 45.1% | 44.5% |
Operating Expenses | ||||
Research & Development | - | - | - | - |
Selling, General & Administrative | - | 849.0M | 609.4M | 390.4M |
Other Operating Expenses | 1.9B | 1.4B | 895.7M | 643.4M |
Total Operating Expenses | 1.9B | 2.3B | 1.5B | 1.0B |
Operating Income | 890.9M | 917.5M | 1.5B | 960.2M |
Operating Margin % | 8.5% | 11.0% | 15.1% | 13.8% |
Non-Operating Items | ||||
Interest Income | - | 80.2M | 48.5M | 32.3M |
Interest Expense | 903.0M | 850.8M | 719.7M | 454.0M |
Other Non-Operating Income | - | - | - | - |
Pre-tax Income | 386.0M | 446.6M | 835.9M | 567.6M |
Income Tax | 166.7M | 208.3M | -196.4M | 136.0M |
Effective Tax Rate % | 43.2% | 46.6% | -23.5% | 24.0% |
Net Income | 219.3M | 238.3M | 1.0B | 431.6M |
Net Margin % | 2.1% | 2.9% | 10.2% | 6.2% |
Key Metrics | ||||
EBITDA | 3.7B | 3.1B | 2.8B | 2.0B |
EPS (Basic) | ₹0.74 | ₹0.75 | ₹2.98 | - |
EPS (Diluted) | ₹0.73 | ₹0.75 | ₹2.98 | - |
Basic Shares Outstanding | 296351351 | 315879846 | 315879846 | - |
Diluted Shares Outstanding | 296351351 | 315879846 | 315879846 | - |
Income Statement Trend
Dr Agarwal's Health Balance Sheet From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Assets | ||||
Current Assets | ||||
Cash & Equivalents | 1.0B | 1.1B | 1.3B | 996.2M |
Short-term Investments | 4.7B | 4.7B | 336.6M | - |
Accounts Receivable | 1.2B | 968.3M | 763.3M | 567.2M |
Inventory | 802.7M | 519.0M | 360.4M | 329.2M |
Other Current Assets | 185.3M | 121.1M | - | - |
Total Current Assets | 7.9B | 7.6B | 3.1B | 2.3B |
Non-Current Assets | ||||
Property, Plant & Equipment | 13.4B | 4.9B | 3.8B | 2.8B |
Goodwill | 19.3B | 11.9B | 7.6B | 3.3B |
Intangible Assets | 4.6B | 2.7B | 2.2B | 387.6M |
Long-term Investments | - | 0 | 0 | 0 |
Other Non-Current Assets | 248.6M | 104.7M | 170.0K | - |
Total Non-Current Assets | 28.8B | 19.9B | 15.1B | 8.0B |
Total Assets | 36.7B | 27.5B | 18.3B | 10.3B |
Liabilities | ||||
Current Liabilities | ||||
Accounts Payable | 1.5B | 1.3B | 1.0B | 890.9M |
Short-term Debt | 1.5B | 1.3B | 956.5M | 630.6M |
Current Portion of Long-term Debt | - | - | - | - |
Other Current Liabilities | 276.3M | 109.7M | 66.3M | 70.1M |
Total Current Liabilities | 4.8B | 4.0B | 3.0B | 2.1B |
Non-Current Liabilities | ||||
Long-term Debt | 8.1B | 8.4B | 7.6B | 5.6B |
Deferred Tax Liabilities | 69.6M | 15.1M | 24.5M | 12.8M |
Other Non-Current Liabilities | - | - | - | - |
Total Non-Current Liabilities | 12.7B | 9.7B | 8.6B | 5.9B |
Total Liabilities | 17.4B | 13.7B | 11.7B | 7.9B |
Equity | ||||
Common Stock | 315.9M | 93.3M | 79.3M | 68.6M |
Retained Earnings | - | -275.0M | -1.0B | -1.9B |
Treasury Stock | - | - | - | - |
Other Equity | - | - | - | - |
Total Shareholders Equity | 19.3B | 13.8B | 6.6B | 2.3B |
Key Metrics | ||||
Total Debt | 9.6B | 9.7B | 8.6B | 6.2B |
Working Capital | 3.2B | 3.6B | 88.6M | 214.8M |
Balance Sheet Composition
Dr Agarwal's Health Cash Flow Statement From 2022 to 2025
Metric | 2025 | 2024 | 2023 | 2022 |
---|---|---|---|---|
Operating Activities | ||||
Net Income | 1.6B | 1.4B | 835.9M | 567.6M |
Depreciation & Amortization | - | - | - | - |
Stock-Based Compensation | 83.8M | 50.6M | 18.3M | 0 |
Working Capital Changes | -1.2B | -356.0M | -301.8M | -332.8M |
Operating Cash Flow | 1.5B | 2.0B | 1.2B | 632.1M |
Investing Activities | ||||
Capital Expenditures | 5.3M | 42.5M | 5.0M | 8.1M |
Acquisitions | -5.2B | -2.9B | -3.2B | -797.1M |
Investment Purchases | - | - | - | - |
Investment Sales | - | - | - | - |
Investing Cash Flow | -5.2B | -2.8B | -3.2B | -789.0M |
Financing Activities | ||||
Share Repurchases | - | - | - | - |
Dividends Paid | -7.9M | -7.7M | -4.3M | -70.0K |
Debt Issuance | 615.2M | 2.5B | 1.7B | 1.1B |
Debt Repayment | -2.0B | -2.2B | -779.6M | -184.5M |
Financing Cash Flow | 5.2B | 6.7B | 4.0B | 1.1B |
Free Cash Flow | 394.3M | 1.1B | 753.0M | 937.4M |
Net Change in Cash | 1.5B | 5.8B | 2.0B | 916.9M |
Cash Flow Trend
Dr Agarwal's Health Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
358.78
Forward P/E
81.93
Price to Book
7.71
Price to Sales
8.03
Profitability Ratios
Profit Margin
5.66%
Operating Margin
13.32%
Return on Equity
1.14%
Return on Assets
0.60%
Financial Health
Current Ratio
1.66
Debt to Equity
49.87
Per Share Data
EPS (TTM)
₹1.27
Book Value per Share
₹59.09
Revenue per Share
₹58.45
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
agarwaleye | 144.1B | 358.78 | 7.71 | 1.14% | 5.66% | 49.87 |
Poly Medicure | 192.9B | 53.60 | 7.09 | 12.24% | 21.18% | 6.52 |
Laxmi Dental | 19.2B | 81.72 | 9.07 | 15.22% | 9.53% | 9.35 |
Tarsons Products | 17.6B | 63.57 | 2.78 | 4.72% | 6.90% | 53.82 |
Prevest Denpro | 6.4B | 35.41 | 6.08 | 17.20% | 28.73% | 0.00 |
Centennial Surgical | 583.5M | 2,482.50 | 1.90 | -4.76% | -3.42% | 108.97 |
Financial data is updated regularly. All figures are in the company's reporting currency.